Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gradient-dose nimotuzumab plus concurrent chemoradiotherapy in locally advanced cervical cancer
ChiCTR2200066975Phase 4Not yet recruiting
- Sponsor
- Chengdu Fifth People's Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nimotuzumab in Cervical Cancer (CC) (4 arms), sponsored by Chengdu Fifth People's Hospital. Primary endpoint: Tumor size. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200066975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066975.